Anzahl der Publikationen: 2
2017
Schoffski, P.; Wozniak, A.; Stacchiotti, S.; Rutkowski, P.; Blay, J.-Y.; Lindner, L. H.; Strauss, S. J.; Anthoney, A.; Duffaud, F.; Richter, S.; Grünwald, V.; Leahy, M. G.; Reichardt, P.; Sufliarsky, J.; Graaf, W. T. van der; Sciot, R.; Debiec-Rychter, M.; Cann, T. van; Marreaud, S.; Lia, M.; Raveloarivahy, T.; Collette, L. und Bauer, S.
(2017):
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
In: Annals of Oncology, Bd. 28, Nr. 12: S. 3000-3008
Powles, T.; McDermott, D. F.; Rini, B.; Motzer, R. J.; Atkins, M. B.; Fong, L.; Joseph, R. W.; Pal, S. K.; Ravaud, A.; Bracarda, S.; Suarez Rodriguez, C.; Maio, M.; Gore, M.; Grünwald, V.; Stähler, M.; Qiu, J.; Thobhani, A.; Huseni, M.; Schiff, C. und Escudier, B.
(2017):
IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC).
In: Annals of Oncology, Bd. 28
Diese Liste wurde am
Sat Dec 21 23:14:24 2024 CET
erstellt.